Posted by Michael Wonder on 13 Jun 2017
Proposal to list a range of Interventional Cardiology products supplied by Edwards Lifesciences
13 June 2017 - PHARMAC is seeking feedback on a proposal to list a range of Interventional Cardiology products supplied by Edwards Lifesciences in Part III of Section H of the Pharmaceutical Schedule from 1 August 2017.
The proposal is subject to approval by the PHARMAC Board or its delegate following this consultation.
In summary, this proposal would result in 15 transcatheter aortic valve devices which are already supplied to DHB Hospitals, being supplied under a proposed national agreement with Edwards, that all DHBs may purchase under. This agreement is not a sole supply agreement, and DHBs may continue to purchase other suppliers’ brands of transcatheter aortic valve devices.
